Synthesis and evaluation of new peptide-linked doxorubicin conjugates as prodrugs activated by prostate-specific antigen

Aloysius, Herve

doi:10.1007/s00044-020-02573-w

Cited by 7 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Organic nanoparticles (polymeric nanoparticles) [16] Redox 2,4-dinitrobenzenesulfonyl Doxorubicin GSH Prodrugs/Organic nanoparticles (micelles) [21] Disulfide linker Doxorubicin and paclitaxel GSH/dithiothreitol Small molecule-drug conjugates [22] Diselenide linker Paclitaxel H 2 O 2 /dithiothreitol Organic nanoparticles (polymeric-nanoparticles) [22] Azobenzene 9-aminocamptothecin Azoreductase Polymer-drug conjugates [23] ROS Phenylboronic ester 5-Fluorouracil H 2 O 2 Prodrugs [30] Aminoacrylate Paclitaxel 1 O 2 Prodrugs/small molecule-drug conjugates [28] Thioketal Mitoxantrone KO 2 Organic nanoparticles (polymeric nanoparticles) [29] pH Hydrazone Doxorubicin 5-6 Organic nanoparticles(dendrimers)/gold nanoparticles/ mesoporous silica nanoparticles/antibody-drug conjugates [36] Silyl ether Docetaxel 5-6 Organic nanoparticles [37] β-thiopropionate Camptothecin 5-6 Organic nanoparticles (micelles)/silver nanoparticles [38] Imine Methotrexate 5-6 Organic nanoparticles (polymeric nanoparticles) [39] Oxime Gemcitabine 5-6 Peptide-drug conjugates [40] Enzyme Glycerophospholipid Capsaicin secretory phospholipase A2 Organic nanoparticles (liposomes) [44] Glucuronide linker auristatin E β-glucuronidase Prodrugs/antibody-drug conjugates/Proteins [45] Quinone propionic acids 7-ethyl-10hydroxycamptothecin DT-diaphorase Prodrugs [46] Camptothecin DT-diaphorase Prodrugs [43] Phe-Arg-Arg-Gly Doxorubicin cathepsin B Organic nanoparticles (polymeric nanoparticles) [47] Ala-Ser-Chg-Gln Doxorubicin prostate-specific antigen Prodrugs [48] (3) A reversible linker between the pro-moiety and the parent drug must be present to allow stimuli-responsive controlled release of active drugs without the creation of any cytotoxic byproducts.…”

Section: Design and Concept Of Stimuli-responsive Theranostic Prodrugmentioning

confidence: 99%

“…Longqin Hu et al have developed a doxorubicin-derived peptide prodrug molecule for prostate cancer. [48] They have used the modified peptide sequence of prostate-specific antigen, glutaryl-Hyp-Ala-Ser-Chg-Gln. The Ser-Leu linkage of the prodrug molecules got cleaved in blood and cultured hepatocytes by neprilysin, an integral membrane-bound metallopeptidase (Figure 26), and released free doxorubicin through a cyclization activation mechanism.…”

Section: Enzyme-activable Prodrugsmentioning

confidence: 99%

“…Longqin Hu et al . have developed a doxorubicin‐derived peptide prodrug molecule for prostate cancer [48] . They have used the modified peptide sequence of prostate‐specific antigen, glutaryl‐Hyp‐Ala‐Ser‐Chg‐Gln.…”

Section: Ros‐activable Prodrugsmentioning

confidence: 99%

See 2 more Smart Citations

Stimuli‐Responsive Prodrug Chemistries for Cancer Therapy

Bargakshatriya,

Pramanik

2023

ChemBioChem

View full text Add to dashboard Cite

Prodrugs are pharmacologically inactive, chemically modified derivatives of active drugs, which, following in vivo administration, is converted to the parent drugs through chemical or enzymatic cleavage. The prodrug approach holds tremendous potential to create the enhanced version of an existing pharmacological agent and leverage those improvements to augment the drug molecules' bioavailability, targeting ability, therapeutic‐efficacy, safety, and marketability. Especially in cancer therapy, prodrug application has received substantial attention. A prodrug can effectively broaden the therapeutic window of its parent drug by enhancing its release at targeted tumor‐sites while reducing its access to healthy cells. The spatiotemporally controlled‐release can be achieved by manipulating the chemical, physical, or biological stimuli present at the targeted tumor site. The critical strategy comprises of drug‐carrier linkages that respond to physiological or biochemical stimuli in the tumor milieu to yield the active drug form. This review will focus on the recent advancements in development of various fluorophore‐drug conjugates that are widely used for real‐time monitoring of drug delivery. The use of different stimuli‐cleavable linkers and the mechanisms of linker cleavage will be discussed. Finally, the review will conclude with a critical discussion on the prospects and challenges that might impede the future development of such prodrugs.

show abstract